

TODAY'S NEWS

Alzheimer Study

Alzheimer's disease has long affected many people worldwide. In the US alone one in nine people over the age of 65 are affected. Global Clinical Trials has joined the fight to treat this disease through its cooperation in the STEADFAST Study. The placebo-control study adds on to patients' normal, day to day medication with new, currently investigated medication to treat mild Alzheimer's.

Opioid Dependence

A risk of many medication is dependence over time, an issue that is particularly prominent with opioid. To help address this issue, a new medication, Bunavail, has been introduced. This prescription medicine seeks to treat opioid dependence alongside counseling and psychosocial treatment. Bunavail has been shown to use less total buprenorphine, an addictive opioid common to many tablet medications, per dosage. Global Clinical Trials is undergoing trials to test the efficacy of the new drug in hopes to reach a wider market.



The AIReal Study

Is there a better drug out there than the active drug in your inhaler? The AIReal Study asks this question as the new generation of asthma-inhibiting drug, generic Advair sponsors Global Clinical Trials. This clinical research study is investigating whether the study drug (generic Advair) is as good as, better than, or worse than Advair Diskus, which is already on the market to treat asthma.

The study is also looking whether generic Advair and Advair Diskus are better than placebo an inactive substitute for the study drug. The study takes about 8 weeks in which the participating patient will receive an inhaler with the drug generic Advair or an inactive drug. The case study will hopefully find promising results for asthma patients with a better delivery of relief by the trial drug, generic Advair.



Tardive Dyskinesia Study

Global Clinical Trials is currently working on a wide number of studies, particularly emphasizing efforts to treat Tardive Dyskinesia, an involuntary movement disorder that affects as many as 500,000 people in the United States alone. Currently two studies are being offered to help work towards treatment for the disorder. Both studies are working towards developing treatment for this currently untreatable disorder through placebo-control methods that place safety of patients and efficacy in treatment above all else, an effort that Global Clinical Trials is proud to be a part of.

Illuminate 301 Study

The Illuminate-301 Study aims to find a new treatment for teenagers of the ages 13-17 managing Schizophrenia symptoms. Teen schizophrenia treatments are limited due to current medications for schizophrenia only having jurisdiction to adults and further tests must be evaluated for the drug to be extended to teens. The Illuminate- 301 study is trying to extend that jurisdiction by measuring the safety and effectiveness of the study medication (lurasidone) in treating schizophrenia in teenagers. Interested teens must first go a screening process to determine whether they meet the requirements to join this clinical research study. The requirements can be overviewed by contacting Global Clinical trials.

